All News

New Cancerguard Blood Test for Multicancer Early Detection Now Available in the US
September 10, 2025

Exact Sciences launches Cancerguard, a groundbreaking blood test for early cancer detection, aiming to transform cancer screening and save lives.

Prior CT Scans Found Linked With Higher Risk of Pregnancy Loss and Birth Defects
September 10, 2025

Although overall risk was just slightly elevated, study authors recommend alternative imaging methods when appropriate for women of childbearing age.

First Generic GLP-1 RA Approved for Weight Management in the US: Daily Dose
September 10, 2025

Your daily dose of the clinical news you may have missed.

A Family Physician on How to Connect Patients to Mental Health Resources in the Community
September 10, 2025

Family physician Teresa Lovins, MD, highlights key community mental health resources primary care clinicians should know to support patients in crisis.

Cervical Cancer Screening Guidelines: Key Updates for Primary Care Physicians
September 09, 2025

Expert discusses when to start screening, available test options, and recommended intervals for women aged 21 to 65 years.

Positive Topline Results on Long-Term Safety Reported for Rocatinlimab in Moderate to Severe Atopic Dermatitis
September 09, 2025

Rocatinlimab offers promise as a novel T-cell rebalancing therapy that targets the OX40 receptor, with maintenance dosing as infrequently as every 8 weeks.

9 States Ranked Highest for Population Vaccination
September 09, 2025

Northeastern states consistently ranked highest on measures including rates of flu vaccination across age groups, number of teens vaccinated against HPV, and older individuals with shingles vaccination.

Phase 3 Data Confirm Strong Immune Response With Pfizer-BioNTech LP.8.1 COVID-19 Vaccine for 2025–2026 Season
September 09, 2025

New data show the LP.8.1-adapted COVID-19 vaccine generates ≥4-fold antibody increases in older and high-risk adults, with no new safety concerns.

Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
September 09, 2025

Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.

Pharmacy-Based FIT Distribution May Expand CRC Screening: Daily Dose
September 09, 2025

Your daily dose of the clinical news you may have missed.